Compound: Pomalidomide
SMILES: O=C1NC(=O)CCC1N2C(=O)c3c(N)cccc3C2=O
InChIKey: UVSMNLNDYGZFPF-UHFFFAOYSA-N
Synonyms: Pomalidomide, 19171-19-8, Actimid, CC-4047, Pomalyst, Imnovid, 4-Aminothalidomide, 4-Amino-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione, 1H-Isoindole-1,3(2H)-dione, 4-amino-2-(2,6-dioxo-3-piperidinyl)-, 3-Amino-N-(2,6-dioxo-3-piperidyl)phthalimide, IMiD 3, CC 4047, IMID-3, 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione, IMiD3, Pomalidomida, D2UX06XLB5, CC4047, CHEBI:72690, DTXSID40893458, 4-amino-2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione, Phthalimide, 3-amino-N-(2,6-dioxo-3-piperidyl)-, pomalidomidum, RefChem:55885, L04AX06, DTXCID801323473, 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione, MFCD12756407, 4-Amino-2-(2,6-dioxo-3-piperidinyl)isoindole-1,3-dione, s1567, 4-amino-2-(2,6-dioxopiperidin-3-yl)-2,3-dihydro-1H-isoindole-1,3-dione, 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline, S-3APG, Pomalidomide [USAN:INN], UNII-D2UX06XLB5, Pomalidomid, Pomalidomide?, HSDB 8222, Pomalyst (TN), 443919-33-3, IMiD1, Pomalidomide (Standard), 4-amino-2-(2,6-dioxo-3-piperidinyl)-1H-Isoindole-1,3(2H)-dione, POMALIDOMIDE [MI], POMALIDOMIDE [INN], POMALIDOMIDE [JAN], 3-amino-N-(2,6-dioxo-3-piperidyl)phthalamide, POMALIDOMIDE [USAN], 3-Aminophthalimidoglutarimide, POMALIDOMIDE [VANDF], MLS006011261, CHEMBL43452, POMALIDOMIDE [WHO-DD], SCHEMBL369172, GTPL7348, orb1305562, Pomalidomide (JAN/USAN/INN), POMALIDOMIDE [EMA EPAR], 3-aminio-phthalimido-glutarimide, SCHEMBL19250920, BDBM65456, IMID-4047, Pomalidomide - Bio-X trade mark, CDC-394, Pomalidomide, >=98% (HPLC), s-3-amino-phthalimido-glutarimide, UVSMNLNDYGZFPF-UHFFFAOYSA-N, GLXC-06238, HMS3655G05, HMS3744K07, HMS5079E16, POMALIDOMIDE [ORANGE BOOK], EBC-11137, HY-10984R, NSC767909, NSC775351, AKOS013400288, CCG-264684, CS-0165, DB08910, FA30210, NSC-767909, NSC-775351, SB16552, NCGC00346551-01, NCGC00346551-03, NCGC00346551-07, NCGC00346551-09, AC-26970, AS-17905, BP-24477, BP164278, DA-21486, HY-10984, SMR004703012, SY054807, 3-(3-AMINO)-PHTALAMIDO-GLUTARIMIDE, P2074, SW218099-2, D08976, EN300-317097, AB01565777_02, F230365, SR-01000941573, Q7227206, SR-01000941573-1, BRD-A12994259-001-02-1, 4-amino-2-(2,6-dioxo-3-piperidyl)isoindole-1,3-dione, Z1269642575, 2-(2,6-Dioxopiperidin-3-yl)-4-amino-isoindole-1,3-dione, 4-amino-2-(2,6-dioxo(3-piperidyl))isoindoline-1,3-dione, 4-Amino-2-[(3RS)-2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione
Theoretical properties:
molecular_formula: C13H11N3O4
molecular_weight: 273.24 g/mol
exact_mass: 273.07495584 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 2
hydrogen_bond_acceptor_count: 5
rotatable_bond_count: 1
heavy_atom_count: 20
topological_polar_surface_area: 110 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
physical_state: Solid yellow powder
color: Solid yellow powder
solubility: Limited to low solubility into organic solvents ... low solubility in all pH solutions (about 0.01 mg/mL)
Descriptions:
pubchem: Pomalidomide is an aromatic amine that is thalidomide substituted at position 4 on the isoindole ring system by an amino group. Used for the treatment of multiple myeloma in patients who failed to respond to previous therapies. It has a role as an antineoplastic agent, an angiogenesis inhibitor and an immunomodulator. It is a member of isoindoles, an aromatic amine, a dicarboximide and a member of piperidones. It is functionally related to a thalidomide.
chebi: An aromatic amine that is thalidomide substituted at position 4 on the isoindole ring system by an amino group. Used for the treatment of multiple myeloma in patients who failed to respond to previous therapies.
chembl: POMALIDOMIDE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Pomalidomide, sold under the brand name Pomalyst among others, is an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma. It inhibits angiogenesis, the formation of new blood vessels.
Pomalidomide was approved for medical use in the United States in February 2013, and in the European Union in August 2013. It is available as a generic medication.